NanoViricides, Inc. (NYSE American: NNVC) has announced the shipment of its drug candidate NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners. Patient enrollment and dosing are expected to begin following the completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. This strain has been associated with higher mortality rates compared to the Clade II strain responsible for the 2022 global outbreak. NanoViricides noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections. The shipment makes the drug locally available should it be utilized in response efforts.
NanoViricides believes that successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola. The drug is designed to target viruses directly, potentially offering a new approach to treating infections that currently lack effective therapies. The company’s nanoviricide technology involves creating special purpose nanomaterials that mimic host cell receptors, thereby neutralizing viruses before they can infect cells.
The Phase II trial in the DRC represents a significant step forward for NanoViricides, which has been developing NV-387 for several viral indications. The drug is also being investigated for respiratory syncytial virus (RSV), COVID-19, influenza, and other respiratory viral infections. The company has stated that NV-387 could serve as a broad-spectrum antiviral, addressing unmet medical needs across multiple viral diseases.
The DRC has been heavily impacted by MPox, with thousands of cases reported annually. The availability of a potential treatment could have significant public health implications, especially given the severity of the Clade I strain. The World Health Organization has declared MPox a public health emergency of international concern, highlighting the need for effective interventions.
NanoViricides’ progress in advancing NV-387 to Phase II trials underscores the company’s commitment to addressing viral threats. The successful outcome of the trial could pave the way for regulatory approvals and broader use of the drug. For more details, the full press release is available at https://ibn.fm/CTIZc.
Investors and stakeholders can find the latest news and updates relating to NNVC in the company’s newsroom at https://ibn.fm/NNVC. NanoViricides continues to focus on advancing its drug candidates through clinical development, with the goal of bringing novel antiviral therapies to market.
